

Heiner Wedemeyer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8572569/heiner-wedemeyer-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

579
papers

28,099
citations

79
h-index

150
g-index

694
ext. papers

33,711
ext. citations

6.1
avg, IF

6.99
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 579 | Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness.. <i>CardioVascular and Interventional Radiology</i> , 2022 , 45, 696 | 2.7 | 0 |
| 578 | Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , 2022 , | 13.4 | 6 |
| 577 | Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.. <i>Virus Evolution</i> , 2022 , 8, veac007 | 3.7 | 1 |
| 576 | Nosocomial infections in female compared with male patients with decompensated liver cirrhosis.. <i>Scientific Reports</i> , 2022 , 12, 3285 | 4.9 | |
| 575 | Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study.. <i>Critical Care</i> , 2022 , 26, 92 | 10.8 | 0 |
| 574 | Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , | 18.8 | 18 |
| 573 | FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. <i>Biomedicines</i> , 2022 , 10, 1018 | 4.8 | |
| 572 | Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial.. <i>Critical Care</i> , 2022 , 26, 134 | 10.8 | 2 |
| 571 | Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair.. <i>Scandinavian Journal of Gastroenterology</i> , 2022 , 1-8 | 2.4 | |
| 570 | Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 32, 223-229 | 2.2 | 2 |
| 569 | Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. <i>Intensive Care Medicine Experimental</i> , 2021 , 9, 57 | 3.7 | 1 |
| 568 | Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany.. <i>Deutsches A&#x0308;rzblatt International</i> , 2021 , 118, 797-798 | 2.5 | |
| 567 | A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection.. <i>Viruses</i> , 2021 , 13, | 6.2 | 1 |
| 566 | Virale Hepatitiden hach wie vor hufig und wichtig!. <i>Gastroenterologe</i> , 2021 , 16, 415-416 | 0.1 | |
| 565 | Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1582-1587 | 2.2 | 0 |
| 564 | Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , 2021 , | 19.2 | 3 |
| 563 | Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1185-1193 | 2.2 | 4 |

| | | | |
|-----|---|------|----|
| 562 | Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. <i>Transplant Infectious Disease</i> , 2021 , 23, e13522 | 2.7 | 3 |
| 561 | Diet-refractory NASH in an elderly woman. <i>Gut</i> , 2021 , 70, 1924-1945 | 19.2 | |
| 560 | Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 4 |
| 559 | Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , 2021 , 41, 1815-1823 | 7.9 | 0 |
| 558 | Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. <i>Liver International</i> , 2021 , 41, 949-955 | 7.9 | 5 |
| 557 | Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , 2021 , 138, 350-353 | 2.2 | 69 |
| 556 | Hepatitis E: An update on One Health and clinical medicine. <i>Liver International</i> , 2021 , 41, 1462-1473 | 7.9 | 8 |
| 555 | Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. <i>Journal of Hepatology</i> , 2021 , 74, 1243-1244 | 13.4 | 10 |
| 554 | Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , 2021 , 12, 684424 | 8.4 | 1 |
| 553 | The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2021 , 41, 2046-2058 | 7.9 | 0 |
| 552 | Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. <i>Frontiers in Public Health</i> , 2021 , 9, 667253 | 6 | 2 |
| 551 | Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab325 | 1 | 0 |
| 550 | Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1206-1218 | 3.4 | 4 |
| 549 | Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021 , 74, 72-82 | 11.2 | 6 |
| 548 | Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , 2021 , 27, 887-899 | 4.5 | 1 |
| 547 | Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. <i>Health Science Reports</i> , 2021 , 4, e290 | 2.2 | 1 |
| 546 | Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00371 | 4.2 | 1 |
| 545 | Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. <i>Cells</i> , 2021 , 10, | 7.9 | 2 |

| | | | |
|-----|---|------|----|
| 544 | Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021 , 10, | 7.9 | 2 |
| 543 | Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. <i>Medicine (United States)</i> , 2021 , 100, e26571 | 1.8 | 1 |
| 542 | BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. <i>Cell Death and Disease</i> , 2021 , 12, 736 | 9.8 | 3 |
| 541 | IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , 2021 , 75, 229-231 | 13.4 | 1 |
| 540 | The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19 | 3.4 | 12 |
| 539 | A transient early HBV-DNA increase during PEG-IFN α therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 410-419 | 3.4 | 1 |
| 538 | Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFN α -based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. <i>Liver International</i> , 2021 , 41, 295-299 | 7.9 | 8 |
| 537 | Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021 , 74, 1053-1063 | 13.4 | 23 |
| 536 | T cell receptor repertoires within liver allografts are different to those in the peripheral blood. <i>Journal of Hepatology</i> , 2021 , 74, 1167-1175 | 13.4 | 1 |
| 535 | Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. <i>Hepatology Communications</i> , 2021 , 5, 97-111 | 6 | 3 |
| 534 | Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 196-204 | 3.4 | 10 |
| 533 | Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1235-1241 | 8.9 | 7 |
| 532 | Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant. <i>Transplant Infectious Disease</i> , 2021 , 23, e13553 | 2.7 | 0 |
| 531 | Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2021 , | 7 | 6 |
| 530 | Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 3 |
| 529 | Increase of β -dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. <i>OncolImmunology</i> , 2021 , 10, 1874159 | 7.2 | 4 |
| 528 | Neue und aktuelle Therapieoptionen bei Hepatitis D. <i>Gastro-News</i> , 2021 , 8, 38-40 | 0 | |
| 527 | Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T-Cell Responses in a Mouse Model. <i>Hepatology Communications</i> , 2021 , 5, 865-881 | 6 | 2 |

| | | | |
|-----|---|------|----|
| 526 | Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2021 , 9, 486-496 | 5.3 | 0 |
| 525 | Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2021 , 117, 102591 | 15.5 | 13 |
| 524 | Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis. <i>Viruses</i> , 2021 , 13, | 6.2 | 2 |
| 523 | Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , 2021 , 21, 296 | 3 | 1 |
| 522 | The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1474-1483 | 34 | 0 |
| 521 | Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 1376-1379 | 2.4 | 1 |
| 520 | Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. <i>Journal of Hepatology</i> , 2021 , | 13.4 | 4 |
| 519 | Impact of the COVID-19 pandemic on patients with liver cirrhosis-the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , 2021 , 59, 954-960 | 1.6 | 0 |
| 518 | Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2021 , | 11.2 | 2 |
| 517 | Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered". <i>Journal of Hepatology</i> , 2021 , 75, 990-992 | 13.4 | 0 |
| 516 | New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. <i>Clinics in Liver Disease</i> , 2021 , 25, 831-839 | 4.6 | 2 |
| 515 | Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2020 , | 6.9 | 17 |
| 514 | Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset?. <i>Frontiers in Immunology</i> , 2020 , 11, 571166 | 8.4 | 8 |
| 513 | Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 974-986 | 3.4 | 7 |
| 512 | High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020 , 40, 2164-2171 | 7.9 | 8 |
| 511 | Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. <i>Liver International</i> , 2020 , 40, 1225-1238 | 7.9 | 7 |
| 510 | Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , 2020 , 72, 1177-1190 | 11.2 | 21 |
| 509 | Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020 , 73, 696-699 | 13.4 | 13 |

| | | | |
|-----|---|------|----|
| 508 | Autophagy alleviates amiodarone-induced hepatotoxicity. <i>Archives of Toxicology</i> , 2020 , 94, 3527-3539 | 5.8 | 4 |
| 507 | HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , 2020 , 4, 983-997 | 6 | 2 |
| 506 | Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , 2020 , 129, 104525 | 14.5 | 1 |
| 505 | Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 690-698 | 3.4 | 8 |
| 504 | Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma. <i>Scientific Reports</i> , 2020 , 10, 2797 | 4.9 | 2 |
| 503 | Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020 , 72, 1112-1121 | 13.4 | 22 |
| 502 | Virale Infektionen bei Lebertransplantierten. <i>Gastroenterologe</i> , 2020 , 15, 227-234 | 0.1 | |
| 501 | Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020 , 40, 1841-1852 | 7.9 | 28 |
| 500 | Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020 , 58, 841-846 | 1.6 | 1 |
| 499 | Hepatitis-A- und -E-Virus-Infektionen [Altes und Neues. <i>Krankenhaushygiene Up2date</i> , 2020 , 15, 375-389 | 0.2 | |
| 498 | Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020 , 103, 169-174 | 3.2 | 3 |
| 497 | Hepatitis D 2020 , 287-298 | | |
| 496 | Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , 2020 , 40, 324-332 | 7.9 | 2 |
| 495 | Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020 , 72, 431-440 | 13.4 | 13 |
| 494 | Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. <i>Hepatology</i> , 2020 , 72, 829-844 | 11.2 | 19 |
| 493 | Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 194-195 | 6.1 | 5 |
| 492 | Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557 | 13.4 | 88 |
| 491 | Autoimmune hepatitis induction can occur in the liver. <i>Liver International</i> , 2020 , 40, 377-381 | 7.9 | 6 |

| | | | |
|-----|--|------|-----|
| 490 | Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1204-1211 | 11.6 | 36 |
| 489 | Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. <i>Scientific Reports</i> , 2020 , 10, 16533 | 4.9 | 7 |
| 488 | Reply to the Letter to the Editor: "Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma". <i>Liver Cancer</i> , 2020 , 9, 363-364 | 9.1 | |
| 487 | Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis. <i>PLoS ONE</i> , 2020 , 15, e0236528 | 3.7 | 1 |
| 486 | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , 2020 , 2, 100168 | 10.3 | 7 |
| 485 | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1359-1368 | 3.4 | 14 |
| 484 | Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health. <i>Pathogens</i> , 2020 , 9, | 4.5 | 27 |
| 483 | Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. <i>Frontiers in Public Health</i> , 2020 , 8, 424 | 6 | 8 |
| 482 | EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218 | 13.4 | 237 |
| 481 | 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020 , 73, S52-S53 | 13.4 | 18 |
| 480 | HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. <i>BMC Gastroenterology</i> , 2020 , 20, 288 | 3 | |
| 479 | Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020 , 58, 341-351 | 1.6 | 2 |
| 478 | Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. <i>Advances in Therapy</i> , 2020 , 37, 4033-4042 | 4.1 | 8 |
| 477 | Virale Infektionen bei Lebertransplantierten. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , 2020 , 23, 240-245 | 0 | |
| 476 | Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2020 , 16, 388-399 | 4.4 | 29 |
| 475 | Hepatitis D 2020 , 133-137 | | |
| 474 | Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020 , 15, e0230893 | 3.7 | 1 |
| 473 | Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020 , 11, 534731 | 8.4 | 6 |

| | | | |
|-----|---|------|----|
| 472 | Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019 , 10, 2076 | 8.4 | 5 |
| 471 | Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019 , 9, 14118 | 4.9 | 5 |
| 470 | The widespread rarity of HBsAg loss in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 190-192 | 18.8 | 1 |
| 469 | Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019 , 71, 673-684 | 13.4 | 10 |
| 468 | Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 67-74 | 2.2 | 3 |
| 467 | Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. <i>Cancer Medicine</i> , 2019 , 8, 3793-3802 | 4.8 | 1 |
| 466 | Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2351-2358 | 4 | 17 |
| 465 | Chronic Hepatitis E is associated with cholangitis. <i>Liver International</i> , 2019 , 39, 1876-1883 | 7.9 | 11 |
| 464 | Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019 , 71, 301-312 | 13.4 | 34 |
| 463 | The Effect of Immunosuppression on Coagulation After Liver Transplantation. <i>Liver Transplantation</i> , 2019 , 25, 1054-1065 | 4.5 | 2 |
| 462 | GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019 , 70, e2-e3 | 13.4 | 9 |
| 461 | Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , 2019 , 24, 133-140 | 1.6 | 8 |
| 460 | Medication adherence among patients with chronic diseases: a survey-based study in pharmacies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019 , 112, 505-512 | 2.7 | 17 |
| 459 | Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019 , 156, 1820-1833 | 13.3 | 23 |
| 458 | Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival. <i>Journal of Pathology: Clinical Research</i> , 2019 , 5, 164-176 | 5.3 | 7 |
| 457 | Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). <i>Substance Abuse: Research and Treatment</i> , 2019 , 13, 1178221819835847 | 1.6 | 5 |
| 456 | Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , 2019 , 11, | 6.2 | 21 |
| 455 | Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2019 , 19, 275-286 | 25.5 | 57 |

| | | | |
|-----|--|------|----|
| 454 | Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 422-431 | 3.4 | 9 |
| 453 | The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1033-1041 | 2.4 | 8 |
| 452 | SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019 , 51, 1962-1971 | 1.1 | 3 |
| 451 | Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019 , 71, 889-899 | 13.4 | 31 |
| 450 | Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. <i>Transplant Infectious Disease</i> , 2019 , 21, e13146 | 2.7 | 18 |
| 449 | PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis. <i>Journal of Hepatology</i> , 2019 , 70, e113-e114 | 13.4 | 3 |
| 448 | LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SoFE pilot study. <i>Journal of Hepatology</i> , 2019 , 70, e129-e130 | 13.4 | 9 |
| 447 | PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019 , 70, e110 | 13.4 | 2 |
| 446 | Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. <i>AIDS Reviews</i> , 2019 , 21, 126-134 | 13.5 | 13 |
| 445 | Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C The TEPS Study. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2019 , 28, 15-26 | 1 | |
| 444 | Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2019 , 71, 1070 | 11.2 | 23 |
| 443 | Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , 2019 , 14, e0224751 | 3.7 | 1 |
| 442 | Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1049-1056 | 2.2 | 4 |
| 441 | NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. <i>Liver Cancer</i> , 2019 , 8, 491-504 | 9.1 | 6 |
| 440 | Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 3 |
| 439 | HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019 , 8, 41-65 | 11.1 | 17 |
| 438 | Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019 , 70, 1008-1015 | 13.4 | 40 |
| 437 | Influenza virus infection as precipitating event of acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019 , 70, 797-799 | 13.4 | 34 |

| | | | |
|-----|--|------|------|
| 436 | Devil hepatitis D: an orphan disease or largely underdiagnosed?. <i>Gut</i> , 2019 , 68, 381-382 | 19.2 | 17 |
| 435 | Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 466-475 | 3.4 | 4 |
| 434 | Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. <i>Antiviral Therapy</i> , 2019 , 24, 117-123 | 1.6 | 10 |
| 433 | Hepatitis E virus replication and interferon responses in human placental cells. <i>Hepatology Communications</i> , 2018 , 2, 173-187 | 6 | 26 |
| 432 | The adverse effects of interferon-free regimens in 149'816 chronic hepatitis C treated Egyptian patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1296-1305 | 6.1 | 9 |
| 431 | Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , 2018 , 25 Suppl 1, 6-17 | 3.4 | 45 |
| 430 | Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1656-1666 | 7 | 31 |
| 429 | Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. <i>Liver International</i> , 2018 , 38, 1951-1964 | 7.9 | 33 |
| 428 | Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 920-929 | 3.4 | 2 |
| 427 | EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511 | 13.4 | 1079 |
| 426 | Development and performance of prototype serologic and molecular tests for hepatitis delta infection. <i>Scientific Reports</i> , 2018 , 8, 2095 | 4.9 | 6 |
| 425 | Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018 , 378, 354-369 | 59.2 | 281 |
| 424 | Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. <i>Addiction</i> , 2018 , 113, 868-882 | 4.6 | 46 |
| 423 | Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , 2018 , 38, 2317-2328 | 7.9 | 6 |
| 422 | Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis-Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1231-1232 | 6.1 | |
| 421 | EASL Clinical Practice Guidelines on hepatitis E virus infection. <i>Journal of Hepatology</i> , 2018 , 68, 1256-1271 | 13.4 | 246 |
| 420 | E-xchange: Hepatitis E and the Risk of Plasma Products for Organ Transplant Recipients. <i>Transplantation</i> , 2018 , 102, 1209-1210 | 1.8 | |
| 419 | Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. <i>Liver International</i> , 2018 , 38, 50-58 | 7.9 | 46 |

| | | | |
|-----|--|------|----|
| 418 | Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018 , 38, 266-277 | 7.9 | 9 |
| 417 | Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018 , 38, 842-850 | 7.9 | 41 |
| 416 | Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. <i>Liver International</i> , 2018 , 38, 834-841 | 7.9 | 5 |
| 415 | Risk factors and seroprevalence of hepatitis E evaluated in frozen-serum samples (2002-2003) of pregnant women compared with female blood donors in a Southern region of Brazil. <i>Journal of Medical Virology</i> , 2018 , 90, 1856-1862 | 19.7 | 8 |
| 414 | Human α Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , 2018 , 9, 510 | 8.4 | 17 |
| 413 | Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2018 , 69, 584-593 | 13.4 | 55 |
| 412 | A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study. <i>Journal of Hepatology</i> , 2018 , 68, S507 | 13.4 | 2 |
| 411 | Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. <i>Liver International</i> , 2018 , 38, 1906-1910 | 7.9 | 11 |
| 410 | Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , 2018 , 69, 982-984 | 13.4 | 17 |
| 409 | Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , 2018 , 35, 843-857 | 4.7 | 10 |
| 408 | Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. <i>PLoS ONE</i> , 2018 , 13, e0197544 | 3.7 | 7 |
| 407 | Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study. <i>Journal of Hepatology</i> , 2018 , 68, S103 | 13.4 | 16 |
| 406 | Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , 2018 , 9, 2275 | 17.4 | 48 |
| 405 | Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1480-1484 | 7 | 22 |
| 404 | Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1384-1394 | 3.4 | 10 |
| 403 | Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial. <i>Journal of Hepatology</i> , 2018 , 68, S90 | 13.4 | 6 |
| 402 | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2018 , 68, S3 | 13.4 | 67 |
| 401 | Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. <i>International Journal of Cardiology</i> , 2018 , 266, 100-105 | 3.2 | 4 |

| | | | |
|-----|--|------|------|
| 400 | Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 516-525 | 6.1 | 42 |
| 399 | Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity. <i>Cell Stress</i> , 2018 , 2, 216-218 | 5.5 | 3 |
| 398 | Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. <i>Antiviral Therapy</i> , 2018 , 23, 211-217 | 1.6 | 42 |
| 397 | Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , 2018 , 68, 851-853 | 13.4 | 3 |
| 396 | Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 663-671 | 13.4 | 34 |
| 395 | HCV [Eine Erkrankung auf dem [Weg zur Eradikation?]. <i>Gastro-News</i> , 2018 , 5, 48-52 | 0 | |
| 394 | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy248 | 1 | 4 |
| 393 | Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , 2018 , 8, 17452 | 4.9 | 16 |
| 392 | HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 856-864 | 18.8 | 32 |
| 391 | Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018 , 6, 1188-1198 | 5.3 | 14 |
| 390 | No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018 , 13, e0199198 | 3.7 | 4 |
| 389 | Automated low-flow ascites pump in a real-world setting: complications and outcomes. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 1082-1089 | 2.2 | 14 |
| 388 | Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals. <i>Journal of Hepatology</i> , 2018 , 68, S532-S533 | 13.4 | 2 |
| 387 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176 | 18.8 | 1196 |
| 386 | Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 1131-1139 | 9.7 | 15 |
| 385 | Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 541-550 | 3.4 | 27 |
| 384 | A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , 2017 , 141, 116-123 | 10.8 | 6 |
| 383 | Exacerbation d'infection par le virus de l'hépatite E au cours d'un traitement par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 244-247 | 0.1 | |

| | | | |
|-----|--|------|-----|
| 382 | Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. <i>Liver International</i> , 2017 , 37, 1468-1475 | 7.9 | 7 |
| 381 | Real-world effectiveness of ombitasvir/paritaprevir/ritonavir-dasabuvir-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 936-943 | 3.4 | 37 |
| 380 | Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 939-945 | 2.2 | 20 |
| 379 | Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. <i>Journal of Hepatology</i> , 2017 , 67, 700-707 | 13.4 | 8 |
| 378 | Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , 2017 , 93, 46-52 | 14.5 | 8 |
| 377 | Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 840-849 | 3.4 | 34 |
| 376 | HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , 2017 , 245, 14-18 | 2.6 | 24 |
| 375 | Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 539-546 | 2.2 | 28 |
| 374 | Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2017 , 55, 848-856 | 1.6 | 11 |
| 373 | Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1541-1543 | 5.1 | 1 |
| 372 | Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 609-618 | 4.7 | 9 |
| 371 | Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , 2017 , 67, 1334-1339 | 13.4 | 20 |
| 370 | Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. <i>Hepatology</i> , 2017 , 66, 1794-1804 | 11.2 | 22 |
| 369 | Reply to Letter to the Editor. <i>Current Opinion in Virology</i> , 2017 , 23, 131 | 7.5 | |
| 368 | Hepatitis E virus infection. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17086 | 51.1 | 244 |
| 367 | Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , 2017 , 17, 215-222 | 25.5 | 78 |
| 366 | The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017 , 215, 139-149 | 7 | 19 |
| 365 | Exacerbation of hepatitis E virus infection during anti-TNF α treatment. <i>Joint Bone Spine</i> , 2017 , 84, 217-219 | 2.9 | 6 |

| | | | |
|-----|---|------|-----|
| 364 | Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017 , 65, 414-425 | 11.2 | 52 |
| 363 | Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 545-551 | 13.4 | 407 |
| 362 | Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017 , 37, 196-204 | 7.9 | 23 |
| 361 | Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , 2017 , 8, 525 | 8.4 | 19 |
| 360 | Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017 , 8, 621 | 8.4 | 31 |
| 359 | Clinical Impact of Liver Biopsies in Liver Transplant Recipients. <i>Annals of Transplantation</i> , 2017 , 22, 108-114 | | 7 |
| 358 | Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam. <i>PLoS ONE</i> , 2017 , 12, e0175304 | 3.7 | 11 |
| 357 | Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. <i>PLoS ONE</i> , 2017 , 12, e0189255 | 3.7 | 32 |
| 356 | SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. <i>Oncotarget</i> , 2017 , 8, 17127-17139 | 3.3 | 16 |
| 355 | Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 187-92 ^{2,2} | | 2 |
| 354 | HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 620-8 | 6.1 | 26 |
| 353 | Hepatitis E Virus Mutations: Functional and Clinical Relevance. <i>EBioMedicine</i> , 2016 , 11, 31-42 | 8.8 | 37 |
| 352 | Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. <i>Hepatology</i> , 2016 , 64, 2274-2276 | 11.2 | 4 |
| 351 | Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. <i>Current Opinion in Virology</i> , 2016 , 20, 112-118 | 7.5 | 23 |
| 350 | The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , 2016 , 36, 473-6 | 7.9 | 2 |
| 349 | Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C*03:04 and modulate NK cell function. <i>Journal of Hepatology</i> , 2016 , 65, 252-8 | 13.4 | 28 |
| 348 | Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , 2016 , 4, 333-8 | 5.3 | 22 |
| 347 | Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1168-76 | 4 | 33 |

| | | | |
|-----|---|------|-----|
| 346 | Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. <i>Transplant Infectious Disease</i> , 2016 , 18, 326-32 | 2.7 | 38 |
| 345 | Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2132-9 | 5.9 | 58 |
| 344 | Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , 2016 , 16, 41-48 | 7.5 | 17 |
| 343 | Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1228-1234 | 11.6 | 19 |
| 342 | Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016 , 62, 561-7 | 11.6 | 72 |
| 341 | Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. <i>PLoS ONE</i> , 2016 , 11, e0145409 | 3.7 | 5 |
| 340 | Hepatitis E 2016 , 69-73 | | |
| 339 | Virale Hepatitiden: Andere virale Infektionen 2016 , 75-79 | | |
| 338 | Hepatitis E 2016 , 69-73 | | |
| 337 | Hepatitis E seroprevalences in pregnant and non-pregnant women in a southern region of Brazil. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 | |
| 336 | Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. <i>Blood</i> , 2016 , 128, 4898-4898 | 2.2 | |
| 335 | Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients receiving opioid substitution therapy in the German Hepatitis C-Registry. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 | |
| 334 | Diversity of clinical presentation and virological characteristics of hepatitis delta: The hepatitis Delta International network (HDIN). <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 | |
| 333 | Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 mono-infection: Final results of the German HepNet Acute HCV IV Study. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 | |
| 332 | Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study. <i>Intervirology</i> , 2016 , 59, 254-255 | 2.5 | 1 |
| 331 | The role of zinc in liver cirrhosis. <i>Annals of Hepatology</i> , 2016 , 15, 7-16 | 3.1 | 82 |
| 330 | Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1821-1830.e6 | 6.9 | 46 |
| 329 | Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , 2016 , 46, 2204-10 | 6.1 | 102 |

| | | | |
|-----|---|------|-----|
| 328 | Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1882-1887 | 4 | 7 |
| 327 | Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1851-1859 | 4 | 4 |
| 326 | Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 305-15 | 3.4 | 19 |
| 325 | Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 512-21 | 3.4 | 81 |
| 324 | Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , 2016 , 65, 1015-23 | 19.2 | 6 |
| 323 | Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , 2016 , 65, 1861-1870 ¹⁹² 146 | 19.2 | 146 |
| 322 | New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016 , 81, 82-9 | 14.5 | 50 |
| 321 | Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. <i>Journal of Infectious Diseases</i> , 2016 , 214, 361-8 | 7 | 37 |
| 320 | Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment. <i>Medical Microbiology and Immunology</i> , 2016 , 205, 263-8 | 4 | 6 |
| 319 | How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 146-52 | 2.2 | 24 |
| 318 | Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016 , 65, 473-82 | 13.4 | 55 |
| 317 | Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , 2016 , 65, 490-8 | 13.4 | 222 |
| 316 | Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2016 , 80, 1-7 | 14.5 | 8 |
| 315 | Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). <i>Lancet Infectious Diseases</i> , 2016 , 16, 606-617 | 25.5 | 89 |
| 314 | Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016 , 214, 1492-1497 | 7 | 78 |
| 313 | Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". <i>Journal of Hepatology</i> , 2016 , 65, 1059-1060 | 13.4 | |
| 312 | Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry. <i>Journal of Hepatology</i> , 2016 , 64, S159 | 13.4 | 8 |
| 311 | In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , 2016 , 65, 1733-43 ² | 19.2 | 101 |

| | | | |
|-----|---|------|-----|
| 310 | Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2016 , 214, 1965-1974 | 7 | 79 |
| 309 | Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 546-7 ^{6.1} | | 4 |
| 308 | Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015 , 64, 1289-95 | 19.2 | 146 |
| 307 | Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1057-64 | 4 | 4 |
| 306 | Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 606.e1-10 | 9.5 | 75 |
| 305 | Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , 2015 , 89, 8304-17 | 6.6 | 28 |
| 304 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C. <i>Visceral Medicine</i> , 2015 , 31, 290-6 | 2.4 | 14 |
| 303 | P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. <i>Journal of Hepatology</i> , 2015 , 62, S524-S525 | 13.4 | 5 |
| 302 | Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon- γ induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 710.e1-9 | 9.5 | 35 |
| 301 | Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. <i>Journal of Immunology</i> , 2015 , 194, 2467-71 | 5.3 | 176 |
| 300 | Evaluation of the COBAS(\square) AmpliPrep/COBAS(\square) TaqMan(\square) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The EXPECT study. <i>Journal of Clinical Virology</i> , 2015 , 67, 67-72 | 14.5 | 17 |
| 299 | Effects of HDV infection and pegylated interferon β treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , 2015 , 64, 469-82 | 19.2 | 39 |
| 298 | Towards interferon-free treatment for all HCV genotypes. <i>Lancet, The</i> , 2015 , 385, 2443-5 | 40 | 18 |
| 297 | Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 1586-94 | 5.8 | 15 |
| 296 | Current Management of HBV/HDV Coinfection and Future Perspectives. <i>Current Hepatology Reports</i> , 2015 , 14, 284-292 | 1 | 3 |
| 295 | Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , 2015 , 35, 2358-62 | 7.9 | 14 |
| 294 | Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , 2015 , 214, 29-32 | 2.6 | 37 |
| 293 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015 , 62, 41-7 ^{13.4} | | 54 |

| | | | |
|-----|---|------|----|
| 292 | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015 , 64, 322-31 | 19.2 | 28 |
| 291 | A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015 , 62, 31-40 | 13.4 | 44 |
| 290 | In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. <i>Molecular Immunology</i> , 2015 , 63, 320-7 | 4.3 | 17 |
| 289 | HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. <i>Antiviral Therapy</i> , 2015 , 20, 177-83 | 1.6 | 16 |
| 288 | Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan?. <i>EBioMedicine</i> , 2015 , 2, 1564-5 | 8.8 | 5 |
| 287 | Estimating HCV disease burden - volume 3 (editorial). <i>Journal of Viral Hepatitis</i> , 2015 , 22 Suppl 4, 1-3 | 3.4 | 11 |
| 286 | Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte. <i>Gastroenterologe</i> , 2015 , 10, 305-309 | 0.1 | 2 |
| 285 | High-resolution determination of human immune cell signatures from fine-needle liver aspirates. <i>European Journal of Immunology</i> , 2015 , 45, 2154-7 | 6.1 | 19 |
| 284 | Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 889-901 | 6.1 | 84 |
| 283 | Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015 , 62, 1013-23 | 11.2 | 39 |
| 282 | Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , 2015 , 35, 2275-84 | 7.9 | |
| 281 | Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 1020-32 | 3.4 | 7 |
| 280 | 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , 2015 , 110, S850-S851 | 0.7 | 4 |
| 279 | Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin. <i>American Journal of Gastroenterology</i> , 2015 , 110, S862 | 0.7 | 4 |
| 278 | Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , 2015 , 6, 270 | 8.4 | 22 |
| 277 | Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015 , 10, e0138503 | 3.7 | 3 |
| 276 | Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015 , 10, e0128069 | 3.7 | 4 |
| 275 | Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015 , 10, e0145622 | 3.7 | 2 |

| | | | |
|-----|---|------|-----|
| 274 | Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2342-49.e1-2 | 6.9 | 41 |
| 273 | Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. <i>Journal of Leukocyte Biology</i> , 2015 , 98, 283-94 | 6.5 | 9 |
| 272 | Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays. <i>Intervirology</i> , 2015 , 58, 283-7 | 2.5 | 11 |
| 271 | Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , 2015 , 35, 1845-52 | 7.9 | 19 |
| 270 | Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. <i>PLoS ONE</i> , 2015 , 10, e0134839 | 3.7 | 3 |
| 269 | In reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2015 , 112, 220 | 2.5 | |
| 268 | Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 85-92 | 6.1 | 26 |
| 267 | Development and evaluation of a baseline-event-anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2014 , 21, e154-63 | 3.4 | 35 |
| 266 | The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 34-59 | 3.4 | 271 |
| 265 | Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014 , 34, 1207-15 | 7.9 | 5 |
| 264 | ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , 2014 , 370, 1973-82 | 59.2 | 754 |
| 263 | Compromised function of natural killer cells in acute and chronic viral hepatitis. <i>Journal of Infectious Diseases</i> , 2014 , 209, 1362-73 | 7 | 80 |
| 262 | Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 544-5 | 6.1 | |
| 261 | A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. <i>Gastroenterology</i> , 2014 , 147, 1008-11.e7; quiz e15-6 | 13.3 | 137 |
| 260 | Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. <i>Journal of Hepatology</i> , 2014 , 61, 976-83 | 13.4 | 20 |
| 259 | HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. <i>Lancet Infectious Diseases</i> , 2014 , 14, 678-679 | 25.5 | 61 |
| 258 | EASL Recognition Awardee for 2014: Prof. Geoff-Dusheiko. <i>Journal of Hepatology</i> , 2014 , 61, 466-8 | 13.4 | |
| 257 | Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <i>New England Journal of Medicine</i> , 2014 , 370, 1604-14 | 59.2 | 488 |

| | | | |
|-----|--|------|----|
| 256 | Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , 2014 , 60, 508-20 | 11.2 | 7 |
| 255 | Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2014 , 16, 333-9 | 2.7 | 34 |
| 254 | Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. <i>Hepatology</i> , 2014 , 60, 1112-3 | 11.2 | 21 |
| 253 | The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 568-77 | 3.4 | 18 |
| 252 | Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014 , 61, 482-91 | 13.4 | 18 |
| 251 | Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. <i>Gastroenterology</i> , 2014 , 147, 119-131.e3 | 13.3 | 26 |
| 250 | Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014 , 60, 191-6 | 13.4 | 30 |
| 249 | Safety and performance of liver biopsies in liver transplant recipients. <i>Clinical Transplantation</i> , 2014 , 28, 585-9 | 3.8 | 12 |
| 248 | Hepatitis C virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 769-79 | 3.4 | 19 |
| 247 | Immunopathogenesis of Hepatitis D 2014 , 231-241 | | |
| 246 | Increased HEV seroprevalence in patients with autoimmune hepatitis. <i>PLoS ONE</i> , 2014 , 9, e85330 | 3.7 | 49 |
| 245 | In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity. <i>PLoS ONE</i> , 2014 , 9, e105375 | 3.7 | 10 |
| 244 | Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. <i>PLoS ONE</i> , 2014 , 9, e108751 | 3.7 | 13 |
| 243 | Hepatitis E in Germany--an under-reported infectious disease. <i>Deutsches A&#x0308;rzteblatt International</i> , 2014 , 111, 577-83 | 2.5 | 58 |
| 242 | Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , 2014 , 63, 1150-8 | 19.2 | 37 |
| 241 | Hepatitis E virus infection in a hematopoietic stem cell donor. <i>Bone Marrow Transplantation</i> , 2014 , 49, 159-60 | 4.4 | 26 |
| 240 | Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C. <i>Zeitschrift Fur Gastroenterologie</i> , 2014 , 52, 749-756 | 1.6 | 2 |
| 239 | How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. <i>Viral Immunology</i> , 2014 , 27, 7-13 | 1.7 | 5 |

| | | | |
|-----|---|------|-----|
| 238 | Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014 , 60, 87-97 | 11.2 | 159 |
| 237 | Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 744-50 | 3.4 | 20 |
| 236 | Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014 , 21 Suppl 1, 60-89 | 3.4 | 140 |
| 235 | The impact of hepatitis E in the liver transplant setting. <i>Journal of Hepatology</i> , 2014 , 61, 1418-29 | 13.4 | 99 |
| 234 | Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2014 , 34, 1452-63 | 7.9 | 45 |
| 233 | Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study. <i>HIV Medicine</i> , 2014 , 15, 245-50 | 2.7 | 16 |
| 232 | Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 836-45 | 2.2 | 19 |
| 231 | High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 1090-7 | 2.2 | 20 |
| 230 | UEG Week Vienna 2014 cutting edge symposium: Today's Science, Tomorrow's Medicine session features the immune system - a driving force in digestive health and disease. <i>United European Gastroenterology Journal</i> , 2014 , 2, 149-50 | 5.3 | 1 |
| 229 | Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1927-8 | 27.4 | 68 |
| 228 | Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. <i>Journal of Viral Hepatitis</i> , 2014 , 21, e169-70 | 3.4 | 4 |
| 227 | Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 1278-85 | 2.2 | 9 |
| 226 | Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease. <i>Transplant Infectious Disease</i> , 2014 , 16, 958-67 | 2.7 | |
| 225 | PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e94512 | 3.7 | 15 |
| 224 | Anti-HDV IgM as a marker of disease activity in hepatitis delta. <i>PLoS ONE</i> , 2014 , 9, e101002 | 3.7 | 31 |
| 223 | Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , 2014 , 9, e110857 | 3.7 | 13 |
| 222 | Virale Hepatitiden: andere virale Infektionen 2014 , 1-6 | | |
| 221 | Hepatitis E 2014 , 1-6 | | |

| | | | |
|-----|--|------|-----|
| 220 | Treatment of hepatitis Delta. <i>Clinical Liver Disease</i> , 2013 , 2, 237-239 | 2.2 | 4 |
| 219 | Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800 | 13.4 | 88 |
| 218 | The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1365-72 | 6.1 | 30 |
| 217 | Results of single-center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin. <i>Pediatric Transplantation</i> , 2013 , 17, 343-7 | 1.8 | 29 |
| 216 | 504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , 2013 , 58, S207 | 13.4 | 3 |
| 215 | Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). <i>European Journal of Radiology</i> , 2013 , 82, 1207-12 | 4.7 | 40 |
| 214 | Hepatitis E virus infection: multiple faces of an underestimated problem. <i>Journal of Hepatology</i> , 2013 , 58, 1045-6 | 13.4 | 23 |
| 213 | Treatment options for hepatitis delta virus infection. <i>Current Infectious Disease Reports</i> , 2013 , 15, 31-8 | 3.9 | 58 |
| 212 | Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. <i>Liver International</i> , 2013 , 33, 722-6 | 7.9 | 126 |
| 211 | Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013 , 13, 497-506 | 25.5 | 73 |
| 210 | Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 76-8 | 24.2 | 6 |
| 209 | Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. <i>Journal of Virology</i> , 2013 , 87, 6172-81 | 6.6 | 82 |
| 208 | Immunopathogenesis of hepatitis E virus infection. <i>Seminars in Liver Disease</i> , 2013 , 33, 71-8 | 7.3 | 38 |
| 207 | Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013 , 62, 760-5 | 19.2 | 132 |
| 206 | O232: Hepatitis E: are serologic tests good enough and reliable?. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 12-14 | 12.4 | 124 |
| 205 | Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013 , 25, 1259-70 | 2.2 | 7 |
| 204 | PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013 , 58, 524-37 | 11.2 | 38 |
| 203 | Proteoglycans act as cellular hepatitis delta virus attachment receptors. <i>PLoS ONE</i> , 2013 , 8, e58340 | 3.7 | 51 |

| | | | |
|-----|---|------|-----|
| 202 | Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. <i>PLoS ONE</i> , 2013 , 8, e55285 | 3.7 | 82 |
| 201 | High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. <i>PLoS ONE</i> , 2013 , 8, e78094 | 3.7 | 25 |
| 200 | Chronic hepatitis e in heart transplant recipients. <i>American Journal of Transplantation</i> , 2012 , 12, 3128-338.7 | | 120 |
| 199 | Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 387-95 | 3.4 | 5 |
| 198 | Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 537-46 | 3.4 | 49 |
| 197 | Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country?. <i>Transplant Infectious Disease</i> , 2012 , 14, 103-6 | 2.7 | 35 |
| 196 | Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , 2012 , 55, 695-708 | 11.2 | 126 |
| 195 | Enrichment of regulatory T cells in acutely rejected human liver allografts. <i>American Journal of Transplantation</i> , 2012 , 12, 3425-36 | 8.7 | 28 |
| 194 | Natural history of acute and chronic hepatitis C. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2012 , 26, 401-12 | 2.5 | 160 |
| 193 | Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. <i>Hepatology</i> , 2012 , 56, 2398-403 | 11.2 | 29 |
| 192 | HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. <i>Liver International</i> , 2012 , 32, 1415-25 | 7.9 | 34 |
| 191 | Interferon- β for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. <i>Antiviral Therapy</i> , 2012 , 17, 1029-37 | 1.6 | 17 |
| 190 | Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. <i>Journal of Hepatology</i> , 2012 , 56, 115-22 | 13.4 | 54 |
| 189 | Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. <i>Journal of Hepatology</i> , 2012 , 56, 520-6 | 13.4 | 107 |
| 188 | High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. <i>Journal of Hepatology</i> , 2012 , 56, 1063-1069 | 13.4 | 31 |
| 187 | Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. <i>Journal of Hepatology</i> , 2012 , 57, 260-6 | 13.4 | 21 |
| 186 | HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. <i>Journal of Clinical Virology</i> , 2012 , 53, 110-5 | 14.5 | 28 |
| 185 | Pathogenesis and treatment of hepatitis e virus infection. <i>Gastroenterology</i> , 2012 , 142, 1388-1397.e1 | 13.3 | 223 |

| | | | |
|-----|---|------|------|
| 184 | Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , 2012 , 96, 51-8 | 10.8 | 2 |
| 183 | Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients. <i>Gastroenterology Insights</i> , 2012 , 4, e28 | 2.1 | 6 |
| 182 | Sind sich Jugendliche über die Gefahren einer Hepatitis-B-Virusinfektion als Geschlechtskrankheit bewusst?. <i>Monatsschrift Fur Kinderheilkunde</i> , 2012 , 160, 477-483 | 0.2 | |
| 181 | Update on the Management of HBV-HDV Coinfection. <i>Current Hepatitis Reports</i> , 2012 , 11, 95-101 | | |
| 180 | Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 1-8 | 3.4 | 37 |
| 179 | Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- α 2a treatment. <i>Antiviral Therapy</i> , 2012 , 17, 305-12 | 1.6 | 20 |
| 178 | Interferon β -stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1351-62 | 7 | 37 |
| 177 | Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. <i>Journal of Immunology</i> , 2012 , 188, 6055-62 | 5.3 | 36 |
| 176 | Hepatitis delta and HIV infection. <i>Seminars in Liver Disease</i> , 2012 , 32, 120-9 | 7.3 | 21 |
| 175 | Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. <i>Endoscopy</i> , 2012 , 44, 48-52 | 3.4 | 30 |
| 174 | Gender differences in patient receiving liver transplantation for viral hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2012 , 50, 760-5 | 1.6 | 3 |
| 173 | Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. <i>Viral Immunology</i> , 2012 , 25, 442-7 | 1.7 | 12 |
| 172 | New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. <i>Gut</i> , 2012 , 61, 1647-52 | 19.2 | 21 |
| 171 | Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2584-93 | 27.4 | 1089 |
| 170 | Angiopoietin-2 in acute liver failure. <i>Critical Care Medicine</i> , 2012 , 40, 1499-505 | 1.4 | 14 |
| 169 | Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. <i>Antiviral Therapy</i> , 2012 , 17, 1049-58 | 1.6 | 14 |
| 168 | Performance of HCV-Core Antigen Testing in Liver Transplanted Patients. <i>Transplantation</i> , 2012 , 94, 7 | 1.8 | |
| 167 | Treatment of Hepatitis E in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2012 , 94, 543 | 1.8 | |

| | | | |
|-----|---|------|-----|
| 166 | Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , 2012 , 7, e43143 | 3.7 | 33 |
| 165 | Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012 , 23, 560-8 | 1 | 17 |
| 164 | Acute HCV 2012 , 13-20 | | |
| 163 | Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). <i>Digestive and Liver Disease</i> , 2011 , 43, 491-7 | 3.3 | 104 |
| 162 | 1255 CHRONIC HEPATITIS E IN IMMUNOSUPPRESSED PATIENTS BEYOND LIVER- AND KIDNEY TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011 , 54, S495 | 13.4 | 4 |
| 161 | Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , 2011 , 50, 292-6 | 14.5 | 67 |
| 160 | Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. <i>Journal of Hepatology</i> , 2011 , 54, 1273-85 | 13.4 | 107 |
| 159 | Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. <i>Journal of Hepatology</i> , 2011 , 55, 38-44 | 13.4 | 44 |
| 158 | The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5 Δ 32 mutation. <i>Journal of Hepatology</i> , 2011 , 55, 1201-6 | 13.4 | 20 |
| 157 | Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , 2011 , 55, 1121-31 | 13.4 | 237 |
| 156 | Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011 , 55, 554-563 | 13.4 | 43 |
| 155 | 382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX. <i>Journal of Hepatology</i> , 2011 , 54, S153 | 13.4 | 2 |
| 154 | Hepatitis delta virus. <i>Lancet, The</i> , 2011 , 378, 73-85 | 40 | 351 |
| 153 | Is there a need for liver disease monitoring in HIV patients in Africa?. <i>Antiviral Therapy</i> , 2011 , 16, 287-9 | 1.6 | 2 |
| 152 | Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , 2011 , 16, 915-24 | 1.6 | 67 |
| 151 | Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 562-70 | 3.4 | 19 |
| 150 | Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e175-8 | 3.4 | 1 |
| 149 | Development of a protocol for the quantitative determination of HBeAg using the Elecsys \square HBeAg immunoassay. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e179-83 | 3.4 | 13 |

| | | | |
|-----|--|------|-----|
| 148 | Hepatitis D revival. <i>Liver International</i> , 2011 , 31 Suppl 1, 140-4 | 7.9 | 32 |
| 147 | Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. <i>Liver International</i> , 2011 , 31, 1395-405 | 7.9 | 34 |
| 146 | Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. <i>Antiviral Research</i> , 2011 , 92, 90-5 | 10.8 | 22 |
| 145 | Telomerase gene mutations are associated with cirrhosis formation. <i>Hepatology</i> , 2011 , 53, 1608-17 | 11.2 | 107 |
| 144 | Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. <i>Hepatology</i> , 2011 , 54, 60-9 | 11.2 | 146 |
| 143 | Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011 , 54, 443-51 | 11.2 | 132 |
| 142 | The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011 , 54, 1947-55 | 11.2 | 207 |
| 141 | Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 1092-8 | 2.4 | 80 |
| 140 | Hepatitis E: an emerging infectious disease in Germany?. <i>Zeitschrift Fur Gastroenterologie</i> , 2011 , 49, 1255-7 | 2.4 | 22 |
| 139 | Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. <i>Journal of Virology</i> , 2011 , 85, 7613-21 | 6.6 | 39 |
| 138 | Successful clearance of hepatitis C virus with pegylated interferon β -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1343-4 | 2.4 | 8 |
| 137 | Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011 , 87, 223-38 | 2 | 2 |
| 136 | Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2648-56 | 4.3 | 10 |
| 135 | Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. <i>Vaccine Journal</i> , 2011 , 18, 1943-50 | | 32 |
| 134 | Peginterferon plus adefovir versus either drug alone for hepatitis delta. <i>New England Journal of Medicine</i> , 2011 , 364, 322-31 | 59.2 | 303 |
| 133 | Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. <i>PLoS Pathogens</i> , 2011 , 7, e1002045 | 7.6 | 94 |
| 132 | Simultaneous mitral valve replacement and liver transplantation. <i>Thoracic and Cardiovascular Surgeon</i> , 2011 , 59, 506-8 | 1.6 | 4 |
| 131 | Quantitative HBSAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010 , 30, 430-7 | 7.9 | 66 |

| | | | |
|-----|---|------|-----|
| 130 | Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010 , 59, 1430-45 | 19.2 | 54 |
| 129 | Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 2022-9 | 9.7 | 64 |
| 128 | Membranous Budd-Chiari syndrome in Caucasians. <i>Scandinavian Journal of Gastroenterology</i> , 2010 , 45, 226-34 | 2.4 | 14 |
| 127 | Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. <i>Zeitschrift Fur Gastroenterologie</i> , 2010 , 48, 258-63 | 1.6 | 13 |
| 126 | Of guinea pigs and men—an unusual case of jaundice. <i>Zeitschrift Fur Gastroenterologie</i> , 2010 , 48, 33-7 | 1.6 | 2 |
| 125 | Treatment of HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 919-28 | 4 | 30 |
| 124 | Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 31-40 | 24.2 | 264 |
| 123 | Hepatitis delta: immunopathogenesis and clinical challenges. <i>Digestive Diseases</i> , 2010 , 28, 133-8 | 3.2 | 44 |
| 122 | Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010 , 52, 493-500 | 13.4 | 96 |
| 121 | Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. <i>Journal of Hepatology</i> , 2010 , 52, 514-22 | 13.4 | 311 |
| 120 | Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. <i>Journal of Hepatology</i> , 2010 , 52, 627-9 | 13.4 | 38 |
| 119 | The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries. <i>Journal of Hepatology</i> , 2010 , 53, 221 | 13.4 | 4 |
| 118 | Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. <i>Gastroenterology</i> , 2010 , 138, 1885-97 | 13.3 | 154 |
| 117 | Hepatitis E in HIV-positive patients in a low-endemic country. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 598-9 | 3.4 | 35 |
| 116 | HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 631-9 | 3.4 | 6 |
| 115 | Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 278-88 | 2.2 | 6 |
| 114 | Evaluation of sound speed for detection of liver fibrosis: prospective comparison with transient dynamic elastography and histology. <i>Journal of Ultrasound in Medicine</i> , 2010 , 29, 1581-8 | 2.9 | 19 |
| 113 | The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , 2010 , 51, 356-7 | 11.2 | 13 |

| | | | |
|-----|--|------|-----|
| 112 | Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010 , 51, 73-80 | 11.2 | 275 |
| 111 | Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. <i>Hepatology</i> , 2010 , 52, 1611-20 | 11.2 | 164 |
| 110 | Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , 2010 , 16, 74-82 | 4.5 | 149 |
| 109 | Hepatitis C new drugs. <i>Journal of the International AIDS Society</i> , 2010 , 13, O29-O29 | 5.4 | 78 |
| 108 | Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice. <i>PLoS ONE</i> , 2010 , 5, e13137 | 3.7 | 55 |
| 107 | Chronic hepatitis E in liver transplant recipients: a significant clinical problem?. <i>Minerva Gastroenterologica E Dietologica</i> , 2010 , 56, 121-8 | 1.6 | 30 |
| 106 | Treatment of chronic hepatitis B. <i>Minerva Gastroenterologica E Dietologica</i> , 2010 , 56, 451-65 | 1.6 | 10 |
| 105 | Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. <i>Clinical Infectious Diseases</i> , 2009 , 49, 317-9; author reply 319 | 11.6 | 43 |
| 104 | The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2009 , 47, 531-40 | 1.6 | 24 |
| 103 | Successful treatment of fulminant hepatitis B during pregnancy. <i>Zeitschrift Fur Gastroenterologie</i> , 2009 , 47, 667-70 | 1.6 | 15 |
| 102 | Adenosine and IFN- α synergistically increase IFN- γ production of human NK cells. <i>Journal of Leukocyte Biology</i> , 2009 , 85, 452-61 | 6.5 | 14 |
| 101 | Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , 2009 , 342, 33-48 | 2.5 | 24 |
| 100 | Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. <i>Hepatology</i> , 2009 , 49, 1449-59 | 11.2 | 10 |
| 99 | Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. <i>Hepatology</i> , 2009 , 50, 799-807 | 11.2 | 433 |
| 98 | Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009 , 50, 1638-45 | 11.2 | 96 |
| 97 | Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. <i>Journal of Medical Virology</i> , 2009 , 81, 2079-88 | 19.7 | 20 |
| 96 | Clearance of chronic HCV infection during acute delta hepatitis. <i>Infection</i> , 2009 , 37, 159-62 | 5.8 | 25 |
| 95 | Expert opinion on the treatment of patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 75-90 | 3.4 | 192 |

| | | | |
|----|---|------|-----|
| 94 | Virological and clinical characteristics of delta hepatitis in Central Europe. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 883-94 | 3.4 | 66 |
| 93 | Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. <i>Liver International</i> , 2009 , 29, 1500-6 | 7.9 | 180 |
| 92 | Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. <i>Vaccine</i> , 2009 , 27, 3099-108 | 4.1 | 4 |
| 91 | Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. <i>Journal of Clinical Virology</i> , 2009 , 46, 210-5 | 14.5 | 74 |
| 90 | Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 1487-90 | 2.4 | 46 |
| 89 | Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 994-1003 | 2.4 | 9 |
| 88 | Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. <i>American Journal of Pathology</i> , 2009 , 175, 1483-92 | 5.8 | 96 |
| 87 | Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 179-85 | 4.3 | 56 |
| 86 | Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?. <i>Annals of Hepatology</i> , 2009 , 8, 166-8 | 3.1 | 5 |
| 85 | Gilbert's syndrome and antiviral therapy of hepatitis C. <i>Annals of Hepatology</i> , 2009 , 8, 246-50 | 3.1 | 5 |
| 84 | Treatment of chronic hepatitis B and the implications of viral resistance to therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2008 , 6, 191-9 | 5.5 | 7 |
| 83 | Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. <i>Journal of Hepatology</i> , 2008 , 48, 1019-20; author reply 1020-1 | 13.4 | 20 |
| 82 | The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2008 , 49, 688-94 | 13.4 | 75 |
| 81 | Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?. <i>Journal of Hepatology</i> , 2008 , 49, 862-3 | 13.4 | 3 |
| 80 | 61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. <i>Journal of Hepatology</i> , 2008 , 48, S27-S28 | 13.4 | 7 |
| 79 | Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 339-45 | 6.9 | 61 |
| 78 | Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 860-5 | 5.1 | 35 |
| 77 | Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. <i>Journal of Infectious Diseases</i> , 2008 , 197, 355-60 | 7 | 28 |

| | | | |
|----|---|------|-----|
| 76 | Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 312-20 | 5.9 | 43 |
| 75 | Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2008 , 46, 880-2 | 1.6 | 5 |
| 74 | Hepatitis C virus living off the fat of the land. <i>Hepatology</i> , 2008 , 47, 343-5 | 11.2 | 2 |
| 73 | Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 200-11 | 3.4 | 19 |
| 72 | Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. <i>Journal of Medical Virology</i> , 2008 , 80, 1195-201 | 19.7 | 26 |
| 71 | Prevalence of HBV genotypes in Central and Eastern Europe. <i>Journal of Medical Virology</i> , 2008 , 80, 1707-17 | 11.7 | 42 |
| 70 | GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. <i>Journal of Medical Virology</i> , 2008 , 80, 1933-40 | 19.7 | 18 |
| 69 | Spontaneous clearance of chronic hepatitis C after liver transplantation: are hepatitis C virus-specific T cell responses the clue?. <i>Liver Transplantation</i> , 2008 , 14, 1225-7 | 4.5 | 13 |
| 68 | Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , 2008 , 47, 1856-62 | 11.2 | 226 |
| 67 | Natural history: the importance of viral load, liver damage and HCC. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2008 , 22, 1063-79 | 2.5 | 11 |
| 66 | A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels. <i>Antiviral Therapy</i> , 2008 , 13, 547-554 | 1.6 | 43 |
| 65 | Hepatitis D virus infection--not a vanishing disease in Europe!. <i>Hepatology</i> , 2007 , 45, 1331-2; author reply 1332-3 | 11.2 | 112 |
| 64 | Longer survival of liver transplant recipients with hepatitis virus coinfections. <i>Clinical Transplantation</i> , 2007 , 21, 258-64 | 3.8 | 24 |
| 63 | Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. <i>European Journal of Clinical Investigation</i> , 2007 , 37, 54-64 | 4.6 | 28 |
| 62 | Steroid treatment for severe acute cryptogenic hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2007 , 45, 15-9 | 1.6 | 17 |
| 61 | Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2007 , 45, 1281-328 | 1.6 | 49 |
| 60 | Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. <i>Human Molecular Genetics</i> , 2007 , 16, 1335-42 | 5.6 | 38 |
| 59 | Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. <i>Annals of Internal Medicine</i> , 2007 , 147, 677-84 | 8 | 459 |

| | | | |
|----|---|------|-----|
| 58 | Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 906-9 | 2.2 | 8 |
| 57 | Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 91-2 | 2.2 | 6 |
| 56 | Prevalence of hepatitis C in a German prison for young men in relation to country of birth. <i>Epidemiology and Infection</i> , 2007 , 135, 274-80 | 4.3 | 29 |
| 55 | Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. <i>Journal of Clinical Virology</i> , 2007 , 39, 308-11 | 14.5 | 27 |
| 54 | Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. <i>Virology Journal</i> , 2007 , 4, 58 | 6.1 | 31 |
| 53 | Immune Responses in Acute and Chronic Hepatitis C 2007 , 193-208 | | |
| 52 | Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?. <i>Minerva Gastroenterologica E Dietologica</i> , 2007 , 53, 337-50 | 1.6 | |
| 51 | Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- α 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007 , 12, 303-316 | 1.6 | 17 |
| 50 | Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006 , 43, 250-6 | 11.2 | 195 |
| 49 | Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <i>Hepatology</i> , 2006 , 43, 1311-6 | 11.2 | 35 |
| 48 | Reply:. <i>Hepatology</i> , 2006 , 44, 511-512 | 11.2 | 1 |
| 47 | Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. <i>Journal of Leukocyte Biology</i> , 2006 , 80, 298-308 | 6.5 | 9 |
| 46 | Treating viral hepatitis C: efficacy, side effects, and complications. <i>Gut</i> , 2006 , 55, 1350-9 | 19.2 | 474 |
| 45 | Treatment of acute hepatitis C-how to explain the differences?. <i>Gastroenterology</i> , 2006 , 131, 682-3; author reply 683-4 | 13.3 | 4 |
| 44 | Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. <i>Journal of Hepatology</i> , 2006 , 44, 291-301 | 13.4 | 63 |
| 43 | Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. <i>Journal of Hepatology</i> , 2006 , 45, 770-8 | 13.4 | 44 |
| 42 | Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. <i>Transplantation</i> , 2006 , 81, 808-9 | 1.8 | 20 |
| 41 | Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. <i>Transplant International</i> , 2006 , 19, 828-33 | 3 | 42 |

| | | | |
|----|---|------|-----|
| 40 | Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 256-63 | 3.4 | 144 |
| 39 | Cytotoxic CD4 T cells in viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 505-14 | 3.4 | 102 |
| 38 | Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 734-41 | 3.4 | 16 |
| 37 | Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006 , 12, 3275-82 | 5.6 | 86 |
| 36 | Effects of cyclosporine on human dendritic cell subsets. <i>Transplantation Proceedings</i> , 2005 , 37, 20-4 | 1.1 | 17 |
| 35 | Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. <i>Hepatology Research</i> , 2005 , 31, 18-23 | 5.1 | 5 |
| 34 | Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. <i>Hepatology</i> , 2005 , 41, 832-5 | 11.2 | 158 |
| 33 | Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. <i>Zeitschrift Fur Gastroenterologie</i> , 2005 , 43, 11-6 | 1.6 | 18 |
| 32 | Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. <i>Cancer Research</i> , 2005 , 65, 2457-64 | 10.1 | 500 |
| 31 | Hepatitis B virus: where are we and where are we going?. <i>Methods in Molecular Medicine</i> , 2004 , 96, 415-43 | | 0 |
| 30 | Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004 , 1, 24-5 | | 1 |
| 29 | Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. <i>Clinical Microbiology and Infection</i> , 2004 , 10, 70-2 | 9.5 | 18 |
| 28 | Acute hepatitis C infection: Can immunology teach us the right way to treat?. <i>Current Hepatitis Reports</i> , 2004 , 3, 148-156 | | 2 |
| 27 | Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , 2004 , 40, 98-107.2 | 17.2 | 62 |
| 26 | High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. <i>Journal of Medical Virology</i> , 2004 , 73, 387-91 | 19.7 | 89 |
| 25 | Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , 2004 , 127, 1347-55 | 13.3 | 284 |
| 24 | Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004 , 41, 999-1007 | 13.4 | 35 |
| 23 | Hepatitis C virus mutation affects proteasomal epitope processing. <i>Journal of Clinical Investigation</i> , 2004 , 114, 250-9 | 15.9 | 64 |

| | | | |
|----|---|------|-----|
| 22 | A rare manifestation of Behçet's syndrome: immunological correlates and successful treatment of an esophageal ulcer. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 1385-91 | 4 | 1 |
| 21 | Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. <i>Current Hepatitis Reports</i> , 2003 , 2, 24-31 | | 1 |
| 20 | Analysis and function of delta-hepatitis virus-specific cellular immune responses. <i>Journal of Hepatology</i> , 2003 , 38, 15-16 | 13.4 | 9 |
| 19 | Acute CMV-Colitis in a Patient with a History of Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2003 , 38, 119-122 | 2.4 | 21 |
| 18 | Acute CMV-colitis in a patient with a history of ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2003 , 38, 119-22 | 2.4 | 8 |
| 17 | Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. <i>Journal of Immunological Methods</i> , 2002 , 271, 125-35 | 2.5 | 40 |
| 16 | Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , 2002 , 4, 23-30 | 5 | 77 |
| 15 | Polyethylene glycol-interferon: current status in hepatitis C virus therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl 3, S344-50 | 4 | 12 |
| 14 | Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. <i>Journal of Immunology</i> , 2002 , 169, 3447-58 | 5.3 | 540 |
| 13 | Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. <i>Journal of Virology</i> , 2001 , 75, 11392-400 | 6.6 | 199 |
| 12 | Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. <i>Gut</i> , 2001 , 48, 378-83 | 19.2 | 50 |
| 11 | Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. <i>Journal of Virology</i> , 2001 , 75, 12121-7 | 6.6 | 28 |
| 10 | Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2001 , 36, 426-31 | 2.4 | 18 |
| 9 | Treatment of acute hepatitis C with interferon alfa-2b. <i>New England Journal of Medicine</i> , 2001 , 345, 1452-7 | 37.2 | 634 |
| 8 | Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 5692-7 | 11.5 | 365 |
| 7 | Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. <i>Journal of Hepatology</i> , 1999 , 30, 366-75 | 13.4 | 87 |
| 6 | Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. <i>Transplantation</i> , 1999 , 68, 1503-11 | 1.8 | 20 |
| 5 | Long-term outcome of chronic hepatitis B in heart transplant recipients. <i>Transplantation</i> , 1998 , 66, 1347-53 | 4.8 | 54 |

- 4 Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. *Hepato-Gastroenterology*, **1998**, 45, 1062-8 5
- 3 Antivirals in Acute Hepatitis C 127-131
- 2 Epidemiology and Natural History 403-409
- 1 T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide. *Liver International*, 7.9 0